Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Puma

Roche - Basel

Roche’s T-DM1 activity in breast cancer “outstanding”

Improves survival by six months compared to GSK’s Tykerb/Tyverb

FDA sets new date for Eliquis review in atrial fibrillation

US regulator had asked for more data from Pfizer and BMS

Pfizer calls on pharmacists to promote medicine adherence

Unused medicines cost NHS England £300m per year

Almirall’s IBS drug Constella backed by CHMP

On track to become the first drug specifically approved for the condition

- PMLiVE

Vivus expects knockback from EMA for obesity drug

Setback comes despite US approval for Qsiva/Qsymia

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

- PMLiVE

Sweden’s Tomas Salmonson to chair EMA’s CHMP

He replaces Eric Abadie who retired in April

- PMLiVE

Pfizer’s RA drug tofacitinib tops methotrexate in phase III

Trial results back drug as major new treatment in rheumatoid arthritis

Pfizer forms branded generics sales alliance in China

Forms joint venture with local company Hisun

- PMLiVE

Pfizer’s Andrew Thomas takes up UK comms agency role

Joins London-based Red Door Communications as head of international

Pfizer gets US approval for leukaemia drug Bosulif

FDA grants the tyrosine kinase inhibitor a licence to treat chronic myelogenous leukaemia

- PMLiVE

Pfizer’s Inlyta gets EU approval for advanced kidney cancer

Available as second-line therapy after treatment with pharma firm's own Sutent

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links